WE HAVE 2 NEW TYSABRI EDITORS STARTING 4/15/10! THEY WIL BE POSTING TYSABRI NEWS EVERY DAY!
Thursday, March 31
CNN.com - "Unlikley the drug (Tysabri) will return to the market anytime soon, if at all."
LINK: "In corporate news, Elan (down $3.88 to $3.10, Research) and Biogen Idec (down $3.78 to $34.57, Research) both sank after the companies said that a third patient taking their suspended multiple sclerosis drug Tysabri had contracted a rare neurological disease, making it unlikely the drug will return to the market anytime soon, if at all."